SKL2001 (SKL-2001) is a novel and potent agonist of Wnt/β-catenin signaling pathway with antitumor activity. SKL2001 can disrupt the Axin/β-catenin interaction, thus stabilizing intracellular β-catenin.
Physicochemical Properties
| Molecular Formula | C14H14N4O3 |
| Molecular Weight | 286.291 |
| Exact Mass | 286.106 |
| Elemental Analysis | C, 58.74; H, 4.93; N, 19.57; O, 16.77 |
| CAS # | 909089-13-0 |
| PubChem CID | 16003447 |
| Appearance | White to off-white solid powder |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 595.7±50.0 °C at 760 mmHg |
| Flash Point | 314.1±30.1 °C |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.655 |
| LogP | 0.37 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 21 |
| Complexity | 355 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | O=C(C1C=C(C2=CC=CO2)ON=1)NCCCN1C=CN=C1 |
| InChi Key | PQXINDBPUDNMPE-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C14H14N4O3/c19-14(16-4-2-6-18-7-5-15-10-18)11-9-13(21-17-11)12-3-1-8-20-12/h1,3,5,7-10H,2,4,6H2,(H,16,19) |
| Chemical Name | 5-(Furan-2-yl)-N-(3-imidazol-1-ylpropyl)-1,2-oxazole-3-carboxamide |
| Synonyms | SKL2001Wnt Agonist II SKL-2001 SKL 2001 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | While it has no effect on NF-κB, p53 reporter gene activity, or GSK-3β activity, SKL2001 is an agonist of the Wnt/β-catenin pathway and can also upregulate the expression of Axin2, a downstream target of the Wnt/β-catenin pathway. By stimulating the Wnt/β-catenin pathway, SKL2001 causes osteoblast differentiation (20 and 40 μM) and inhibits preadipocyte differentiation (5, 10 and 30 μM). In 3T3-L1 cells, SKL2001 (5, 10 and 30 μM) stabilizes intracellular β-catenin [1]. HCT116 spheroids are considerably inhibited from proliferating, regardless of cytotoxicity, by SKL2001 (40 μM), and this inhibition is reversible; SKL2001 leads HCT116 spheroids to enter the cell cycle arrest state. E-cadherin expression and round spheroid formation are enhanced by SKL2001 (40 μM) [2]. |
| References |
[1]. Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation. ell Res. 2012 Jan;22(1):237-47. [2]. SKL2001 suppresses colon cancer spheroid growth through regulation of the E-cadherin/β-Catenin complex. Biochem Biophys Res Commun. 2017 Nov 25;493(3):1342-1348. |
Solubility Data
| Solubility (In Vitro) | DMSO : ≥ 96.66 mg/mL (~337.63 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4930 mL | 17.4648 mL | 34.9296 mL | |
| 5 mM | 0.6986 mL | 3.4930 mL | 6.9859 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4930 mL |